Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Boehringer Ingelheim
Merck
Dow
Baxter

Last Updated: May 25, 2022

Investigational Drug Information for Eritoran


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Eritoran?

Eritoran is an investigational drug.

There have been 5 clinical trials for Eritoran. The most recent clinical trial was a Phase 3 trial, which was initiated on April 11th 2016.

The most common disease conditions in clinical trials are Insulin Resistance, Hypersensitivity, and Toxemia. The leading clinical trial sponsors are Eisai Inc., The University of Texas Health Science Center at San Antonio, and UMC Utrecht.

There are thirty US patents protecting this investigational drug and seven hundred and ten international patents.

Recent Clinical Trials for Eritoran
TitleSponsorPhase
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaAustralian and New Zealand Intensive Care Research CentrePhase 4
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaBerry ConsultantsPhase 4
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaGlobal Coalition for Adaptive ResearchPhase 4

See all Eritoran clinical trials

Clinical Trial Summary for Eritoran

Top disease conditions for Eritoran
Top clinical trial sponsors for Eritoran

See all Eritoran clinical trials

US Patents for Eritoran

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Eritoran See Plans and Pricing Combination therapy for inducing immune response to disease IBC Pharmaceuticals, Inc. (Morris Plains, NJ) See Plans and Pricing
Eritoran See Plans and Pricing Methods for treating renal disease Beth Israel Deaconess Medical Center, Inc. (Boston, MA) See Plans and Pricing
Eritoran See Plans and Pricing Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors IBC Pharmaceuticals, Inc. (Morris Plains, NJ) See Plans and Pricing
Eritoran See Plans and Pricing Aptamers specific for TLR-4 and uses thereof APTATARGETS, S.L. (Madrid, ES) See Plans and Pricing
Eritoran See Plans and Pricing Anti-PVRIG antibodies and methods of use Compugen Ltd. (Holon, IL) See Plans and Pricing
Eritoran See Plans and Pricing Uses of 6-aminohexanoic acid to manage bleeding conditions Emory University (Atlanta, GA) See Plans and Pricing
Eritoran See Plans and Pricing Combination therapy for inducing immune response to disease IBC Pharmaceuticals, Inc. (Morris Plains, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Eritoran

Drugname Country Document Number Estimated Expiration Related US Patent
Eritoran Australia AU2014228886 2033-03-15 See Plans and Pricing
Eritoran Canada CA2942514 2033-03-15 See Plans and Pricing
Eritoran European Patent Office EP2970428 2033-03-15 See Plans and Pricing
Eritoran Hong Kong HK1220699 2033-03-15 See Plans and Pricing
Eritoran Japan JP2016516053 2033-03-15 See Plans and Pricing
Eritoran World Intellectual Property Organization (WIPO) WO2014144686 2033-03-15 See Plans and Pricing
Eritoran Australia AU2013302696 2032-08-14 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Boehringer Ingelheim
Merck
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.